May 26, 2016 10:42 AM ET

Pharmaceuticals

Company Overview of Intersect ENT, Inc.

Company Overview

Intersect ENT, Inc., a commercial stage drug-device company, provides therapeutic solutions for patients with ear, nose, and throat conditions in the United States. It offers PROPEL and PROPEL mini drug releasing implants for patients undergoing sinus surgery to treat chronic sinusitis. The company is also developing RESOLVE, a steroid releasing implant for refractory disease for the treatment of patients in the physician office setting; and NOVA, a steroid releasing implant to fit the ostia, or openings, of the dependent sinuses following enlargement of the sinuses. The company was formerly known as Sinexus, Inc. and changed its name to Intersect ENT, Inc. in November 2009. Intersect ENT, I...

1555 Adams Drive

Menlo Park, CA 94025

United States

Founded in 2003

126 Employees

Phone:

650-641-2100

Key Executives for Intersect ENT, Inc.

Chief Executive Officer, President and Director
Age: 45
Total Annual Compensation: $442.4K
Chief Financial Officer
Age: 57
Total Annual Compensation: $357.9K
Chief Operating Officer and Vice President of R&D & Operations
Age: 53
Total Annual Compensation: $324.1K
Chief Commercial Officer
Age: 46
Total Annual Compensation: $319.2K
Vice President of Clinical Affairs
Age: 45
Total Annual Compensation: $263.7K
Compensation as of Fiscal Year 2015.

Intersect ENT, Inc. Key Developments

Intersect ENT, Inc. Announces Results of the Second Cohort of the PROGRESS Study

Intersect ENT, Inc. announced results of the second cohort of the PROGRESS study. The second cohort of PROGRESS is a prospective, randomized, blinded, multi-center trial to assess the safety and efficacy of the company’s investigational NOVA bioabsorbable steroid releasing sinus implant. The NOVA implant is designed to support the sinus opening mechanically while delivering anti-inflammatory medication following surgical interventions such as sinus surgery in the operating room or in-office sinus dilation. NOVA’s unique hourglass shape and lower profile is designed to allow for placement in smaller sinus openings, and may expand the applicable patient population for steroid releasing implants. The NOVA cohort of the PROGRESS study is a prospective, randomized, blinded, multi-center trial of 80 patients designed to assess implant safety and efficacy when placed in the frontal sinuses, which are located behind the forehead. The study met its primary efficacy endpoint, demonstrating a statistically significant 65% relative reduction in the need for post-operative interventions, such as the need for additional surgical procedures or need for oral steroid prescription, compared to surgery alone. The device placement success rate was 100% and there were no device-related adverse events.

Intersect ENT, Inc. Announces Consolidated Unaudited Earnings Results for the First Quarter Ended March 31, 2016; Provides Earnings Guidance for the Full Year of 2016

Intersect ENT, Inc. announced consolidated unaudited earnings results for the first quarter ended March 31, 2016. For the quarter, the company reported revenues of $16,692,000 compared with $13,372,000 for the same period year ago. Loss from operations was $8,406,000 compared with $5,366,000 for the same period year ago. Net loss was $8,221,000 or $0.29 per basic and diluted share compared with $5,338,000 or $0.23 per basic and diluted share for the same period year ago. The increase in revenue is attributable to higher unit sales via the acquisition of new accounts and driving adoption with existing customers. The company provided earnings guidance for the full year of 2016. The company continues to project revenue for 2016 in the range of $78-$80 million. The company is also maintaining its outlook for gross margins in the range of 80-81%, operating expense of approximately $92 million, and net use of cash of approximately $25 million for the year.

Intersect ENT, Inc. Presents at Bank of America Merrill Lynch 2016 Healthcare Conference, May-11-2016 03:00 PM

Intersect ENT, Inc. Presents at Bank of America Merrill Lynch 2016 Healthcare Conference, May-11-2016 03:00 PM. Venue: The Encore at Wynn, 3131 S Las Vegas Blvd, Las Vegas, NV 89109, United States. Speakers: Lisa D. Earnhardt, Chief Executive Officer, President and Director.

Similar Private Companies By Industry

Company Name Region
21st Century Animal Health United States
3 Buds' Organics LLC United States
4P Therapeutics LLC United States
60° Pharmaceuticals, LLC United States
7 Oaks Pharmaceutical Corp. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content. For inquiries, please contact Capital IQ directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Bloomberg L.P. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Intersect ENT, Inc., please visit www.intersectent.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.